Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration to conduct clinical trials for its drug, which is currently not available in China [1] Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, is set to initiate clinical trials for the drug, which is a third-generation platelet aggregation inhibitor [1] - The drug, Prasugrel Hydrochloride Tablets, is indicated for preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1] Industry Summary - The drug is already marketed in over 70 countries and regions globally, indicating its established presence in the international pharmaceutical market [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration for clinical trials of Prasugrel Hydrochloride Tablets, marking a significant step in expanding its product portfolio in the cardiovascular drug market [1]. Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, has been granted a clinical trial approval for Prasugrel Hydrochloride Tablets by the National Medical Products Administration [1]. - Prasugrel Hydrochloride is a third-generation drug that inhibits ADP-induced platelet aggregation, aimed at preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]. - The original developer of Prasugrel is Daiichi Sankyo Co., Ltd., and the drug is currently available in over 70 countries and regions worldwide, although it has not yet been launched in China [1].

关于子公司药物获临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，重药控股股份有限公司（以下简称"公司"）控股子公司重庆医药（集 团）股份有限公司（以下简称"重药股份"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的《药物临床试验批准通知书》，将于近期开展临床试验。 现将有关情况公告如下： 证券代码：000950 证券简称：重药控股 公告编号：2025-066 重药控股股份有限公司 二、其他相关情况 盐酸普拉格雷片原研公司为第一三共株式会社，是第三代的抑制 ADP 激活 的血小板聚集的药物，适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉 综合征、稳定型心绞痛、陈旧性心肌梗塞患者的血栓形成。目前已在全球 70 多 个国家和地区上市（中国境内未上市）。 重药股份投资引进第一三共株式会社的盐酸普拉格雷片技术及独家专利授权， 于 2021 年 8 月提交上市注册申请并获受理。因需进一步完善申报资料，经审慎研 究决定，于 2023 年 7 月主动撤回申请。2025 年 6 月，重药股份临床试验申请获得 受理，具体信息详见公司在巨潮资 ...

Core Viewpoint - Zhongyao Holdings (000950) announced that its subsidiary, Zhongyao Co., has received the clinical trial approval notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which will soon commence clinical trials [1] Company Summary - The drug is indicated for the prevention of thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Chongqing Pharmaceutical Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which is intended for clinical trials [1] Group 1 - The drug Prasugrel Hydrochloride Tablets is a third-generation inhibitor of ADP-induced platelet aggregation [1] - The drug is indicated for the prevention of thrombus formation in patients with acute coronary syndrome after percutaneous coronary intervention, stable angina, and old myocardial infarction [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

1 | | 很高，公司是三家全国性麻精药品批发企业之一，并在 15 个省 | | --- | --- | | | 市拥有区域性批发资格，销售网络覆盖全国 31 个省市及自治区， | | | 其中在四川、重庆、贵州、青海、西藏等 5 个地区具有麻精药品 | | | 经销优势。上半年公司麻精药品实现销售 17.36 亿元，同比增加 | | | 19.07%。 | | | 4、公司财务费用下降明显的原因？ | | | 答：公司持续加强对财务费用的管控，今年以来公司融资成 | | | 本下降趋势明显，上半年财务费用同比下降 1.65 亿元，同比降 | | | 幅为 30.35%。财务费用率创五年同期新低，预计未来还有进一 | | | 步下降空间。 | | | 5、公司与通用技术集团内部协同情况如何？ | | | 答：公司加速推进与通用技术集团旗下医疗机构的协同发 | | | 展，报告期内在全国 22 个省开户 104 家，其中 89 家为等级医院， | | | 同时公司在 2025 年 8 月底，与通用健康、中国医药签订战略合 | | | 作协议。三方将整合资源渠道优势，通过优化供应链全流程管理， | | | 实现药 ...

Core Viewpoint - The company Zhongyao Holdings (000950.SZ) has made significant progress in its share repurchase plan, indicating a commitment to enhancing shareholder value while facing challenges in profitability due to industry pressures [1][2]. Group 1: Share Repurchase Progress - As of August 31, Zhongyao Holdings has repurchased 9.313 million shares, accounting for approximately 0.54% of its total share capital, with a total expenditure of about 49.99 million yuan [1]. - The repurchase plan, initiated on July 11, aims to buy back shares worth between 80 million yuan and 100 million yuan, with a maximum price of 6.6 yuan per share [1]. Group 2: Financial Performance - Revenue has shown a steady increase over the past three years, with figures of 67.83 billion yuan in 2022, 78.4 billion yuan in 2023, and projected 80.56 billion yuan in 2024, reflecting successful business expansion [1]. - However, net profit has declined for three consecutive years, with figures of 0.952 billion yuan in 2022, 0.625 billion yuan in 2023, and 0.283 billion yuan in 2024, representing decreases of 5.29%, 34.41%, and 54.69% respectively [2]. Group 3: Recent Developments and Market Expansion - In the first half of 2025, the company achieved a revenue of 41.188 billion yuan, a year-on-year increase of 3.54%, and a net profit of 0.282 billion yuan, up 18.56% [2]. - The company has expanded its market presence, achieving coverage in all 31 provinces and 164 prefecture-level cities, with 65.85% of revenue coming from outside its home base in Chongqing [2]. - The pharmaceutical wholesale business generated over 95% of revenue, amounting to 39.052 billion yuan, while the e-commerce segment saw a transaction volume of approximately 1 billion yuan, growing by 72% [2][3]. Group 4: Retail and Asset Growth - The retail segment reported revenue of 1.947 billion yuan, with over 850 stores across 22 provinces, and has implemented services in 616 stores in response to national policies [3]. - As of mid-2025, total assets reached 67.95 billion yuan, a 2.57% increase year-on-year, while the debt-to-asset ratio improved to 75.61%, down by 0.67 percentage points [3].

证券日报网讯9月2日晚间，重药控股（000950）发布公告称，截至2025年8月31日，公司通过股份回购 专用证券账户以集中竞价交易方式累计回购股份数量为9，313，000股，约占公司总股本的0.5389%。 ...

Market Overview - On September 2, the Chongqing state-owned enterprise reform sector fell by 1.11% compared to the previous trading day, with *ST Huicheng leading the decline [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Shanghai Sanmao (600689) saw a closing price of 13.79, with an increase of 2.99% and a trading volume of 100,200 shares, totaling 136 million yuan [1] - Chongqing Water (601158) closed at 4.74, up 0.64%, with a trading volume of 156,300 shares, amounting to 7.36878 million yuan [1] - Other notable stocks include Yuzhong Development (000514) at 5.35, down 0.74%, and Jieling Pickles (002507) at 13.25, down 0.97% [1][2] Capital Flow - The Chongqing state-owned enterprise reform sector experienced a net outflow of 178 million yuan from main funds, while retail investors saw a net inflow of 116 million yuan [2] - The table of capital flow indicates that Yuzhong Development (000514) had a net outflow of 6.6107 million yuan from main funds, but a net inflow of 6.9797 million yuan from retail investors [3] Individual Stock Analysis - *ST Huicheng (002168) closed at 4.80, down 4.95%, with a trading volume of 327,300 shares, totaling 159 million yuan [2] - Qianli Technology (601777) closed at 11.77, down 2.73%, with a trading volume of 708,600 shares [2] - Chongqing Port (600279) had a closing price of 5.51, down 0.54%, with a trading volume of 68,500 shares, totaling 3.7841 million yuan [2][3]